Observational studyEndocrine2015
One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study.
Observational study in Endocrine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 57 citations in OpenAlex.
- Liraglutide relieves cardiac dilated function than DPP-4 inhibitors.European journal of clinical investigation · 2018Trial
- GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease.Nature reviews. Nephrology · 2026Review
- Managing Diabetes in Older Adults: Current Approaches in Long-Term Care Facilities.Current diabetes reports · 2025Review
- Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity.Obesity facts · 2023Review
- Advances in understanding and treating diabetic kidney disease: focus on tubulointerstitial inflammation mechanisms.Frontiers in endocrinology · 2023Review
- Use of Glucose-Lowering Agents in Diabetes and CKD.Kidney international reports · 2022Review
- Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients.Journal of endocrinological investigation · 2022Article
- Update on the management of diabetes in long-term care facilities.BMJ open diabetes research & care · 2022Review
- Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.Nature reviews. Nephrology · 2021Review
- Innate immunity in diabetic kidney disease.Nature reviews. Nephrology · 2020Review
- Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.Journal of diabetes · 2019Review
- GLP-1 Receptor Agonists and Kidney Protection.Medicina (Kaunas, Lithuania) · 2019 · on this mapReview
- Sodium butyrate ameliorates insulin resistance and renal failure in CKD rats by modulating intestinal permeability and mucin expression.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2019Article
- The Role of Deprescribing in Older Adults with Chronic Kidney Disease.Drugs & aging · 2018Review
- Simultaneous GLP-1 receptor activation and angiotensin receptor blockade increase natriuresis independent of altered arterial pressure in obese OLETF rats.Hypertension research : official journal of the Japanese Society of Hypertension · 2018Article
- Diabetic nephropathy: newer therapeutic perspectives.Journal of community hospital internal medicine perspectives · 2018Review
- Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease.Journal of the American Society of Nephrology : JASN · 2017Review
- Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2016Review
- Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence.International journal of molecular sciences · 2016Review
- The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies.Clinical pharmacology : advances and applications · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unlike GLP-1, liraglutide is not cleared by the glomerulus and its pharmacokinetic is not altered in patients with mild renal impairment. The aim of our study was to analyze the effects of liraglutide on renal function in patients with type 2 diabetes. A twelve-month longitudinal prospective post-marketing study was performed. According to eGFR (estimated glomerular filtration rate) calculated with CKD-EPI equation, 84 consecutive patients were divided in Group A (eGFR > 90 ml/min) and Group B (eGFR < 90 ml/min). BMI, glucose, HbA1c, serum creatinine, microalbuminuria, and eGFR were evaluated at baseline and after 12 months of treatment. A reduction in fasting plasma glucose (p < 0.01), HbA1c (p < 0.003), BMI (p < 0.01), and systolic (p < 0.01) and diastolic blood pressure (p < 0.006) was recorded irrespective of eGFR category. Concerning renal function, creatinine levels had a trend to decrease in both groups. eGFR did not change in Group A, while it increased in Group B (p < 0.05) independently from the concomitant changes of other parameters. Moreover, seven out of 41 patients of Group B had increased eGFR levels which reached the normal values (>90 ml/min). At baseline, five patients had pathological microalbuminuria, but at 12 months three of them returned to normal albuminuria (p < 0.006). Total microalbuminuria levels improved in both groups (p < 0.02). According to preliminary data in animals, our study shows that liraglutide is effective in preserving eGFR in diabetic patients, increasing it in those with reduced renal function. This was associated with a decrease of frequency of patients positive to microalbuminuria. Further studies are needed to confirm these data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.